Profile data is unavailable for this security.
About the company
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
- Revenue in USD (TTM)813.81m
- Net income in USD-1.71m
- Incorporated1997
- Employees610.00
- LocationACADIA Pharmaceuticals Inc12830 El Camino Real, Suite 400SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 558-2871
- Fax+1 (858) 558-2872
- Websitehttps://acadia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arvinas Inc | 71.30m | -354.80m | 2.27bn | 445.00 | -- | 3.71 | -- | 31.81 | -6.05 | -6.05 | 1.22 | 8.93 | 0.0597 | -- | 12.08 | 160,224.70 | -29.59 | -22.01 | -37.90 | -26.47 | -- | -- | -495.65 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Fortrea Holdings Inc | 3.01bn | -100.60m | 2.27bn | 16.00k | -- | 1.43 | -- | 0.7549 | -1.13 | -1.37 | 33.82 | 17.81 | 0.7036 | -- | 3.10 | 167,050.00 | -2.35 | -- | -2.84 | -- | 16.64 | -- | -3.35 | -- | -- | 0.2534 | 0.5035 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
| Vericel Corp | 207.78m | 451.00k | 2.32bn | 314.00 | 4,989.54 | 9.89 | 429.32 | 11.16 | 0.0096 | 0.0096 | 4.35 | 4.82 | 0.6684 | 4.38 | 4.71 | 661,719.80 | 0.1451 | -3.07 | 0.1621 | -3.50 | 69.50 | 67.87 | 0.2171 | -4.49 | 4.83 | -- | 0.0007 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| Novocure Ltd | 525.66m | -192.74m | 2.37bn | 1.45k | -- | 6.59 | -- | 4.51 | -1.81 | -1.81 | 4.92 | 3.34 | 0.4579 | 3.57 | 7.51 | 361,774.90 | -16.79 | -7.74 | -19.40 | -8.95 | 74.82 | 77.22 | -36.67 | -14.69 | 5.99 | -- | 0.6132 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
| Twist Bioscience Corp | 277.49m | -192.14m | 2.44bn | 919.00 | -- | 4.35 | -- | 8.79 | -3.35 | -3.35 | 4.83 | 9.63 | 0.3565 | 4.87 | 7.04 | 301,943.40 | -24.68 | -30.50 | -27.12 | -33.84 | 38.29 | 36.02 | -69.24 | -113.33 | 5.06 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
| Immunocore Holdings PLC - ADR | 265.83m | -59.44m | 2.45bn | 497.00 | -- | 6.77 | -- | 9.21 | -1.20 | -1.20 | 5.27 | 7.23 | 0.3486 | 0.406 | 5.60 | 534,860.40 | -7.80 | -27.55 | -9.40 | -36.82 | 99.60 | -- | -22.36 | -97.12 | 5.94 | -- | 0.5489 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Iovance Biotherapeutics Inc | 1.90m | -449.64m | 2.48bn | 557.00 | -- | 3.65 | -- | 1,305.10 | -1.82 | -1.82 | 0.0077 | 2.43 | 0.0023 | -- | -- | 3,418.31 | -53.07 | -51.47 | -59.00 | -57.56 | -846.22 | -- | -23,615.70 | -137,873.80 | 4.42 | -- | 0.0015 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
| ACADIA Pharmaceuticals Inc | 813.81m | -1.71m | 2.49bn | 610.00 | -- | 5.37 | 278.94 | 3.07 | -0.0129 | -0.0129 | 4.93 | 2.81 | 1.08 | 1.85 | 10.13 | 1,363,159.00 | -0.2264 | -27.50 | -0.3579 | -32.73 | 92.27 | 95.62 | -0.2101 | -38.35 | 1.86 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
| TG Therapeutics Inc | 289.33m | 41.20m | 2.52bn | 284.00 | 73.93 | 15.74 | 60.89 | 8.71 | 0.2205 | 0.2205 | 1.97 | 1.04 | 1.01 | 0.3567 | 7.86 | 1,095,962.00 | 14.44 | -62.87 | 20.20 | -80.06 | 93.53 | -- | 14.24 | -405.03 | 2.84 | 4.01 | 0.3876 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
| Avidity Biosciences Inc | 10.87m | -228.68m | 2.57bn | 253.00 | -- | 3.09 | -- | 236.32 | -2.95 | -2.95 | 0.1408 | 8.69 | 0.0139 | -- | -- | 42,964.43 | -29.22 | -31.61 | -31.71 | -34.45 | -- | -- | -2,103.78 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| MoonLake Immunotherapeutics | 0.00 | -40.68m | 2.60bn | 50.00 | -- | 4.71 | -- | -- | -0.7501 | -0.7501 | 0.00 | 8.63 | 0.00 | -- | -- | 0.00 | -14.53 | -- | -15.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Denali Therapeutics Inc | 295.39m | -137.25m | 2.65bn | 375.00 | -- | 1.82 | -- | 8.96 | -0.9661 | -0.9661 | 2.09 | 10.21 | 0.1976 | -- | -- | 663,797.80 | -9.18 | -14.98 | -10.91 | -17.71 | -- | -- | -46.46 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
| Apogee Therapeutics Inc | 0.00 | -103.55m | 2.67bn | 91.00 | -- | 3.21 | -- | -- | -2.04 | -2.04 | 0.00 | 14.22 | 0.00 | -- | -- | 0.00 | -21.45 | -- | -22.20 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| 10X Genomics Inc | 625.45m | -264.30m | 2.68bn | 1.26k | -- | 3.73 | -- | 4.29 | -2.24 | -2.24 | 5.30 | 6.01 | 0.6458 | 2.67 | 7.39 | 496,781.60 | -27.29 | -25.52 | -30.80 | -29.05 | 64.62 | 75.88 | -42.26 | -48.53 | 4.45 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
| Azenta Inc | 651.76m | -152.26m | 2.72bn | 3.40k | -- | 1.24 | -- | 4.18 | -2.74 | -2.71 | 11.09 | 40.70 | 0.2242 | 2.86 | 3.44 | 186,216.00 | -5.24 | -0.5934 | -5.64 | -0.6725 | 40.04 | 43.08 | -23.36 | -2.17 | 5.26 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
Data as of May 31 2024. Currency figures normalised to ACADIA Pharmaceuticals Inc's reporting currency: US Dollar USD
63.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 31 Mar 2024 | 42.86m | 26.02% |
| RTW Investments LPas of 31 Mar 2024 | 13.83m | 8.39% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 12.96m | 7.86% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 9.58m | 5.82% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 6.00m | 3.64% |
| EcoR1 Capital, LLCas of 31 Mar 2024 | 5.99m | 3.64% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 3.99m | 2.42% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 3.81m | 2.31% |
| Geode Capital Management LLCas of 31 Mar 2024 | 2.79m | 1.70% |
| D. E. Shaw & Co. LPas of 31 Mar 2024 | 2.64m | 1.60% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
